Catriona Yale Akero Therapeutics, Inc. (AKRO) insider trading activity

Catriona Yale is Chief Development Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 0 shares of AKRO, which is worth approximately $0. The most recent transaction as insider was on Dec 09, 2025, when has been sold 74,800 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Catriona Yale Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 09 2025	SELL Sale (or disposition) back to the issuer	-	74,800 Reduced 100.0%	0 Common Stock
Nov 04 2025	BUY Exercise of conversion of derivative security	$204,418 $24.73 p/Share	8,266 Added 9.95%	74,800 Common Stock
Sep 11 2025	SELL Open market or private sale	$28,350 $43.02 p/Share	659 Reduced 0.72%	90,829 Common Stock
Jul 16 2025	SELL Open market or private sale	$531,700 $53.17 p/Share	10,000 Reduced 9.85%	91,488 Common Stock
Jul 16 2025	BUY Exercise of conversion of derivative security	$198,700 $19.87 p/Share	10,000 Added 8.97%	101,488 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	$21,244 $23.87 p/Share	890 Added 0.96%	91,488 Common Stock
Jun 18 2025	SELL Open market or private sale	$89,553 $54.84 p/Share	1,633 Reduced 1.77%	90,598 Common Stock

Jun 16 2025	SELL Open market or private sale	$547,000 $54.7 p/Share	10,000 Reduced 9.78%	92,231 Common Stock
Jun 16 2025	BUY Exercise of conversion of derivative security	$211,000 $21.1 p/Share	10,000 Added 8.91%	102,231 Common Stock
Jun 10 2025	SELL Open market or private sale	$151,362 $54.0 p/Share	2,803 Reduced 2.95%	92,231 Common Stock
May 15 2025	SELL Open market or private sale	$391,900 $39.19 p/Share	10,000 Reduced 9.52%	95,034 Common Stock
May 15 2025	BUY Exercise of conversion of derivative security	$211,000 $21.1 p/Share	10,000 Added 8.69%	105,034 Common Stock
Apr 15 2025	SELL Open market or private sale	$346,679 $38.21 p/Share	9,073 Reduced 8.72%	95,034 Common Stock
Apr 15 2025	BUY Exercise of conversion of derivative security	$191,440 $21.1 p/Share	9,073 Added 8.02%	104,107 Common Stock
Mar 17 2025	SELL Open market or private sale	$448,800 $44.88 p/Share	10,000 Reduced 9.52%	95,034 Common Stock
Mar 17 2025	BUY Exercise of conversion of derivative security	$211,000 $21.1 p/Share	10,000 Added 8.69%	105,034 Common Stock
Mar 12 2025	SELL Open market or private sale	$27,556 $44.88 p/Share	614 Reduced 0.64%	95,034 Common Stock
Feb 18 2025	SELL Open market or private sale	$502,100 $50.21 p/Share	10,000 Reduced 9.47%	95,648 Common Stock
Feb 18 2025	BUY Exercise of conversion of derivative security	$211,000 $21.1 p/Share	10,000 Added 8.65%	105,648 Common Stock
Jan 27 2025	SELL Open market or private sale	$3,003,183 $56.04 p/Share	53,590 Reduced 35.91%	95,648 Common Stock
Jan 27 2025	SELL Open market or private sale	$2,750,106 $56.04 p/Share	49,074 Reduced 33.91%	95,648 Common Stock
Jan 27 2025	BUY Exercise of conversion of derivative security	$501,602 $9.36 p/Share	53,590 Added 26.42%	149,238 Common Stock
Jan 27 2025	BUY Exercise of conversion of derivative security	$1,035,461 $21.1 p/Share	49,074 Added 25.32%	144,722 Common Stock
Dec 16 2024	SELL Open market or private sale	$264,144 $29.11 p/Share	9,074 Reduced 8.66%	95,648 Common Stock
Dec 16 2024	BUY Exercise of conversion of derivative security	$191,461 $21.1 p/Share	9,074 Added 7.97%	104,722 Common Stock

Catriona Yale

Chief Development Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account